The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings ...

Moderna claims Pfizer-BioNTech’s COVID vaccine infringes on patents it filed between 2010 and 2016 covering its mRNA technology.

Before new versions of the Omicron strain took hold in the U.S., Pfizer Inc. and BioNTech SE had begun tinkering with their widely used Covid-19 vaccine. In May, researchers tracking how ...

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives The trial did not meet one of its ...

--BioNTech SE today reported financial results for the three months ended March 31, 2025 and provided an update on its corporate progress.. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech." We ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which fell below analyst expectations.

BioNTech (NasdaqGS:BNTX) saw its share price increase by 11%, coinciding with significant market activity and major index gains. While the company itself did not have any significant news or ...